Profile data is unavailable for this security.
About the company
NRX Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is developing therapeutics based on its N-methyl-D-aspartate (NMDA) platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and post-traumatic stress disorder (PTSD). The Company has two lead compounds, NRX-100, a proprietary presentation of ketamine and NRX-101, a fixed-dose combination of D-cycloserine (DCS) and lurasidone. The Company is developing NRX-101, a Food and Drug Administration (FDA)-designated investigational therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRX-101 is a combined NMDA/5-HT2A-targeted medicine designed to address both depression and suicidal ideation, consisting of an oral, fixed dose combination of DCS and lurasidone. Its NRX-100 is racemic ketamine, which is a generic anesthetic. The Company is also engaged in the development of its new product, NRX-102.
- Revenue in USD (TTM)0.00
- Net income in USD-30.16m
- Incorporated2017
- Employees2.00
- LocationNRX Pharmaceuticals Inc1201 ORANGE STREET, SUITE 600WILMINGTON 19801United StatesUSA
- Phone+1 (484) 254-6134
- Fax+1 (302) 575-1642
- Websitehttps://www.nrxpharma.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lipocine Inc | -2.85m | -16.35m | 28.02m | 17.00 | -- | 1.37 | -- | -- | -3.11 | -3.11 | -0.5417 | 3.83 | -0.0942 | -- | -- | -167,695.30 | -54.02 | -39.32 | -58.16 | -45.87 | -- | -- | -- | -442.26 | -- | -- | 0.00 | -- | -670.16 | -- | -51.99 | -- | -- | -- |
| NKGen Biotech Inc | 0.00 | -82.95m | 28.12m | 63.00 | -- | -- | -- | -- | -5.24 | -5.24 | 0.00 | -2.68 | 0.00 | -- | -- | 0.00 | -86.93 | -- | -111.69 | -- | -- | -- | -- | -- | -- | -0.6077 | -- | -- | -- | -- | -1,923.83 | -- | -- | -- |
| Aprea Therapeutics Inc | 583.24k | -14.29m | 29.87m | 7.00 | -- | 1.21 | -- | 51.21 | -4.00 | -4.00 | 0.1613 | 4.89 | 0.0221 | -- | -- | 83,320.00 | -54.11 | -68.66 | -63.19 | -77.19 | -- | -- | -2,449.55 | -42,112.84 | -- | -- | 0.00 | -- | -- | -- | 87.32 | -- | 90.61 | -- |
| NRX Pharmaceuticals Inc | 0.00 | -30.16m | 30.93m | 2.00 | -- | -- | -- | -- | -2.95 | -2.95 | 0.00 | -0.1398 | 0.00 | -- | -- | -- | -182.00 | -120.57 | -- | -168.40 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 24.14 | -- | -- | -- |
| Mink Therapeutics Inc | 0.00 | -22.46m | 31.21m | 31.00 | -- | -- | -- | -- | -0.6538 | -0.6538 | 0.00 | -0.5219 | 0.00 | -- | -- | 0.00 | -172.59 | -- | -2,317.47 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 19.77 | -- | -- | -- |
| Dare Bioscience Inc | 2.81m | -30.16m | 31.54m | 23.00 | -- | -- | -- | 11.23 | -0.3444 | -0.3444 | 0.032 | -0.0505 | 0.0863 | -- | 2.12 | 122,082.20 | -92.65 | -109.51 | -463.87 | -246.26 | -- | -- | -1,074.17 | -1,104.55 | -- | -- | -- | -- | -71.92 | -- | 2.54 | -- | 121.37 | -- |
| Brainstorm Cell Therapeutics Inc | 0.00 | -17.19m | 31.92m | 29.00 | -- | -- | -- | -- | -0.4079 | -0.4079 | 0.00 | -0.0803 | 0.00 | -- | -- | 0.00 | -271.62 | -117.19 | -- | -231.65 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 29.18 | -- | -45.34 | -- |
| Acurx Pharmaceuticals Inc | 0.00 | -14.58m | 31.96m | 4.00 | -- | 6.26 | -- | -- | -1.14 | -1.14 | 0.00 | 0.3226 | 0.00 | -- | -- | 0.00 | -170.64 | -- | -243.33 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -20.55 | -- | -- | -- |
| RenovoRx Inc | 0.00 | -10.23m | 32.21m | 8.00 | -- | -- | -- | -- | -1.01 | -1.01 | 0.00 | -0.2805 | 0.00 | -- | -- | 0.00 | -234.38 | -- | -317.07 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -3.47 | -- | -- | -- |
| Viracta Therapeutics Inc | 0.00 | -51.06m | 32.40m | 40.00 | -- | 2.51 | -- | -- | -1.32 | -1.32 | 0.00 | 0.4686 | 0.00 | -- | -- | 0.00 | -66.88 | -86.35 | -97.91 | -106.38 | -- | -- | -- | -11,853.94 | -- | -141.21 | 0.5798 | -- | -- | -- | -3.78 | -- | -- | -- |
| LianBio - ADR | 0.00 | -87.98m | 32.55m | 163.00 | -- | 0.1595 | -- | -- | -0.8195 | -0.8195 | 0.00 | 1.89 | 0.00 | -- | -- | 0.00 | -28.62 | -- | -35.22 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 43.82 | -- | -- | -- |
| Surrozen Inc | 0.00 | -43.04m | 32.72m | 42.00 | -- | 0.5563 | -- | -- | -21.35 | -21.35 | 0.00 | 18.39 | 0.00 | -- | -- | 0.00 | -63.52 | -- | -72.56 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -100.00 | -- | -19.55 | -- | -- | -- |
| Fortress Biotech Inc | 84.51m | -68.67m | 32.89m | 186.00 | -- | 1.14 | -- | 0.3892 | -8.88 | -8.88 | 10.29 | 1.49 | 0.366 | 2.19 | 3.89 | 454,371.00 | -66.76 | -52.50 | -117.74 | -99.46 | 68.45 | 63.17 | -182.40 | -236.94 | 1.26 | -11.31 | 0.9758 | -- | 11.58 | 25.75 | 27.42 | -- | -9.37 | -- |
| Singular Genomics Systems Inc | 2.91m | -94.82m | 33.11m | 255.00 | -- | 0.1847 | -- | 11.37 | -1.30 | -1.30 | 0.04 | 2.42 | 0.0098 | 0.2182 | 3.94 | 11,415.69 | -31.96 | -- | -33.80 | -- | -19.17 | -- | -3,257.30 | -- | 9.77 | -- | 0.0474 | -- | 280.52 | -- | -4.34 | -- | -- | -- |
